David Hochman Biography and Net Worth

Mr. Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. He previously served as Managing Partner of Orchestra Medical Ventures, an investment firm focused on creating high-impact medical device therapies.

Mr. Hochman has also served as President of Accelerated Technologies, Inc., a medical device accelerator company now owned by Orchestra BioMed. Mr. Hochman has over 25 years of healthcare entrepreneurial, venture capital, and investment banking experience. From December 2016 to September 2023, Mr. Hochman served as a member of the board of directors of Motus GI (Nasdaq: MOTS), a Nasdaq-listed medical technology company in which Orchestra has a strategic investment and as its Chairman of the Board from December 2016 to April 2023. Mr. Hochman was a co-founder and until September 2020 served as a board member of Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system.

Prior to joining Orchestra Medical Ventures, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early-stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc., during which time he led financing transactions for over twenty early-stage companies, raising over $420 million. From 1999 to 2006, Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750 million. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer-lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013 for over $600 million. Mr. Hochman earned a B.A. with honors from the University of Michigan.